Karolinska Institutet registered an observational study of dementia with Lewy bodies (DLB) on ClinicalTrials.gov on 5 June 2026, under the acronym Find-DLB (NCT07629349). The record lists the study as recruiting, with an actual start date of 1 January 2020 and support from Swedish Research Council grants. Participants are recruited from cognitive clinics in Stockholm and must have at least one core clinical feature of DLB, such as visual hallucinations, parkinsonism, cognitive fluctuations or probable REM sleep behaviour disorder. The registration states that clinical assessments, neuroimaging and fluid biomarkers will be collected, and that Stockholm data will be combined with other national and international cohorts to increase statistical power and allow replication. It is therefore not a newly built multi-site consortium: it is one clinic-based cohort, retrospective to 2020 and prospective since, that intends to pool.
The cohort has already produced published description rather than progression figures. In European Geriatric Medicine, published online on 8 December 2025, investigators reported 143 patients presenting to a specialised cognitive clinic with clinical features of DLB. After full evaluation, 88 met clinical criteria for DLB, 35 for Parkinson's disease dementia, 14 had mild cognitive impairment and 6 had another dementia. The authors noted that probable REM sleep behaviour disorder was recorded less often than in other cohorts, which they attributed to the difficulty of capturing it in a routine clinical interview. A registration carries no results, and the public summary sets out what will be measured rather than any rate of decline.
The timing matters because the field still lacks agreed yardsticks. A systematic review and meta-analysis published online in Clinical Parkinsonism and Related Disorders on 17 June 2026 screened 9,162 titles and found only 17 longitudinal biomarker studies in DLB meeting its criteria, covering about 460 patients with mild cognitive impairment with Lewy bodies or DLB. Fifteen used imaging and two used fluid biomarkers. The authors concluded that DAT-SPECT and FDG-PET showed promise as monitoring markers but that no single biomarker is yet suitable for tracking progression. Meanwhile CervoMed has said it plans to begin a global phase 3 trial of neflamapimod in about 300 people with DLB in the second half of 2026, randomised one to one for 32 weeks against placebo with a 48 week extension, using change in the Clinical Dementia Rating Sum of Boxes as the primary endpoint and excluding people with plasma p-tau181 at or above 21.0 pg/mL to enrich for those without Alzheimer's co-pathology.
Find-DLB is not the only longitudinal effort. Mayo Clinic has run a study of longitudinal imaging biomarkers of disease progression in DLB (NCT03582488) since 2018, enrolling by invitation and estimating completion in September 2027. What the Stockholm registration adds is a clinic-derived population rather than a highly selected research sample, which is also its main constraint: naturalistic cohorts vary in how completely core features and follow-up are recorded, and pooled data across countries carry differences in scanning, assays and diagnostic practice. Whether the study yields progression estimates precise enough to power a trial will not be known until data, not plans, are published.